HDAC inhibitors and cardiac safety

Clin Cancer Res. 2007 Feb 1;13(3):1068; author reply 1068-9. doi: 10.1158/1078-0432.CCR-06-1715.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Clinical Trials as Topic
  • Depsipeptides / antagonists & inhibitors
  • Depsipeptides / therapeutic use*
  • Electrocardiography / methods
  • Enzyme Inhibitors / pharmacology*
  • Heart Diseases / chemically induced*
  • Heart Diseases / pathology
  • Histone Deacetylase Inhibitors*
  • Humans
  • Hydroxamic Acids / pharmacology
  • Maximum Tolerated Dose
  • Neuroendocrine Tumors / drug therapy*
  • Risk
  • Sulfonamides
  • Torsades de Pointes / chemically induced

Substances

  • Antineoplastic Agents
  • Depsipeptides
  • Enzyme Inhibitors
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • LAQ824
  • Sulfonamides
  • romidepsin
  • belinostat